Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.42 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | IL2 | P60568 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12389840 | 0.92 | MAPT (0.41) | MAPK14MAPTPDK2RAB9ASMN1; SMN2 | |
| SCHEMBL12365419 | 0.92 | MAPK14 (0.43) | MAPK14IL2PDK2RAB9AKMT2A | |
| SCHEMBL12389723 | 0.90 | LMNA (0.45) | PYGLRAB9AHTR5A | |
| SCHEMBL12365802 | 0.88 | IL2 (0.42) | MAPK14IL2PDK2RAB9AKMT2A | |
| SCHEMBL12365045 | 0.88 | IGF1R (0.38) | MAPK14MAPTPDE4DRAB9ASMN1; SMN2 | |
| SCHEMBL12390297 | 0.87 | MAPK14 (0.44) | MAPK14PYGLMAPTPDK2RAB9A | |
| SCHEMBL12365807 | 0.87 | MAPK14 (0.47) | MAPK14IL2MAPTPDK2MEN1 | |
| SCHEMBL12390109 | 0.86 | MAPK14 (0.40) | MAPK14MAPTPDK2RAB9ASMN1; SMN2 | |
| SCHEMBL13384432 | 0.86 | AURKA (0.33) | MAPTPDE4DRAB9ASMN1; SMN2PDE4A | |
| SCHEMBL12365439 | 0.85 | MAPK14 (0.43) | MAPK14MAPTPDK2SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | MAPK14 3304/4885PYGL 4343/4885IL2 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.